Synopsis
- This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and forward looking statements of 247 industry executives have been captured in our in-depth survey.
- The geographical scope of the research is global - drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific and Africa and Middle East.
- The report covers data and analysis on buyer expenditure, procurement and industry developments.
- Key topics covered include pharmaceutical industry buyer expenditure activity, procurement behaviors and strategies, threats and opportunities, economic outlook and business confidence.
- In the report, buyers identify what suppliers need to do to maintain their business and the key actions being taken by industry players to overcome the leading business threats.
- The report examines current practices and provides future expectations over the next 12–24 months.
- The report provides qualitative analysis of the key industry threats and opportunities and contains full survey results.
Summary
“Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry” is a new report by ICD Research that analyzes how Pharmaceutical industry companies’ procurement expenditure, business strategies and practices are set to change in 2012–2013. This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies future growth of buyers and suppliers, M&A and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.
Scope
The report features the opinions of global Pharmaceutical industry respondents related to the following:
- Revenue growth and future developments in business structure.
- Merger and acquisition activity.
- Capital expenditure and change in staff recruitment activity.
- Key regions of growth.
- Key industry threats and opportunities.
- Key supplier actions and e-procurement.
- Annual procurement budgets and change in procurement expenditure.
- Change in supplier selection and procurement objectives.
Reasons To Buy
Why was the report written?
This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global pharmaceutical industry executives. The report provides data and analysis on buyer expenditure, procurement and developments within the global pharmaceutical industry. This report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies. This report identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends and business confidence within global pharmaceutical industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviours, creating a gap in presenting the business outlook of the industry. In an effort to bridge this gap, ICD Research created this primary-research based report by gathering the opinions of multiple stake holders in the value-chain of the global pharmaceutical industry.
What is the current market landscape and what is changing?
Growing economic concerns in the later part of 2011 in Europe and North America motivated organizations to rethink about their growth prospects for 2012. According to a World Bank projection in January 2012, world economic growth will be truncated to 2.5% in 2012 and 3.1% in 2013, as compared with a projection of 3.6% in June 2011, following the financial turmoil in Europe and weak growth prospects in emerging nations.
What are the key drivers behind recent market changes?
ICD Research survey results demonstrate that respondents’ optimism of revenue growth expectations increased in 2011 by six percentage points, as compared with 2010. Additionally, respondents who expect an increase in growth have declined in 2012 by 9 percentage points as compared with 2011. This relative decrease in growth optimism may be seen as a reflection of financial performances of prominent pharmaceutical companies in the fourth quarter ended December 31, 2011 (Q4 2011).
What makes this report unique and essential to read?
“Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry” is a new report by ICD Research that analyzes how pharmaceutical industry companies’ procurement expenditure, business strategies and practices are set to change in 2012–2013. This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies future growth of buyers and suppliers, M&A and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.
Key Highlights
More optimism in industry
Throughout the global pharmaceutical industry, 47% of respondents are ‘more optimistic’ about revenue growth for their company over the next 12 months relative to the previous 12 months. A further 28% of respondents are ‘neutral’ about revenue growth as compared with 23% who are ‘less optimistic’ about their company’s revenue prospects.
Rethinking growth prospects
Growing economic concerns in the later part of 2011 in Europe and North America motivated organizations to rethink about their growth prospects for 2012. According to a World Bank projection in January 2012, world economic growth will be truncated to 2.5% in 2012 and 3.1% in 2013, as compared with a projection of 3.6% in June 2011, following the financial turmoil in Europe and weak growth prospects in emerging nations.
China, India and Brazil to enjoy leading growth rates
It is anticipated that emerging markets such as China, India and Brazil will enjoy leading growth rate in 2012, with China expected to continue its double digit growth similar to 2011, due to an increase in the Chinese Government’s expenditure and individual consumer spending. With the rise in number of affluent Chinese population, diseases such as cancer, diabetes and cardiovascular ailments are on the rise, enhancing the demand for drug development targeted towards the domestic Chinese market.
Revenue expected to sustain growth levels
Optimism regarding revenue growth of global pharmaceutical manufacturers, CROs and CMOs remained stable in 2011 and decreased marginally in 2012. However, it is projected that revenue expectations in both emerging and recovering developed markets will sustain growth levels in 2012.
Reduction in drug costs
Following the global financial crisis in 2008–2009, and the subsequent European debt crisis in 2011, global pharmaceutical manufacturing companies have accelerated their focus to reduce the cost of drugs leading to a renewed evaluation of opportunities in the outsourcing of manufacturing activities. These incidents favor the growth of the pharmaceutical market in emerging economies and also present opportunities for CROs and CMOs.
